Azacitidine for the treatment of relapsed and refractory AML in older patients.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

Item
http://www.wikidata.org/entity/Q53226227
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter studyAcute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signalingDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.Hypomethylating Agents as a Therapy for AML.Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemiaTreatment of relapsed/refractory acute myeloid leukaemia in adults.Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectivesEfficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiamutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents
P2860

Azacitidine for the treatment of relapsed and refractory AML in older patients.

Item
http://www.wikidata.org/entity/Q53226227
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Azacitidine for the treatment of relapsed and refractory AML in older patients.
@en
Azacitidine for the treatment of relapsed and refractory AML in older patients.
@nl
type
label
Azacitidine for the treatment of relapsed and refractory AML in older patients.
@en
Azacitidine for the treatment of relapsed and refractory AML in older patients.
@nl
prefLabel
Azacitidine for the treatment of relapsed and refractory AML in older patients.
@en
Azacitidine for the treatment of relapsed and refractory AML in older patients.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Azacitidine for the treatment of relapsed and refractory AML in older patients.
@en
P2093
P304
P31
P356
10.1016/J.LEUKRES.2014.11.009
P433
P478
P50
P577
P5875
P698